Home Tags NanoViricides
The company intends to perform certain core safety pharmacology studies to ensure safety of the drug candidate at Calvert Labs.
The company is working to complete the necessary required safety pharmacology studies that would allow it to apply to the FDA for permission to begin human clinical trials.
NanoViricides' first drug, NV-HHV-101, is a potential dermal treatment for the shingles virus.
TheraCour Pharma would receive $4 million in milestone payments with the successful completion of Phase I and II human clinical trials.